This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
by Zacks Equity Research
RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Pharmaceutical Stocks Hit New Highs Amid Market Volatility
by Bryan Hayes
During this time of heightened market volatility, it pays to be invested in the right places.
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
by Zacks Equity Research
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the preceding trading day.
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
by Zacks Equity Research
The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
by Zacks Equity Research
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
by Zacks Equity Research
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
by Zacks Equity Research
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatment.
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
Pacira Q4 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed fourth-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Is FlexShares Credit-Scored US Corporate Bond ETF (SKOR) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SKOR
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
by Zacks Equity Research
VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert. Stock down.
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up
by Zacks Equity Research
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
by Zacks Equity Research
BLUE and GILD are in the spotlight this week on key updates.
The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant
by Zacks Equity Research
Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant are included in this Analyst Blog.
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors
by Zacks Equity Research
Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors have been highlighted in this Screen of The Week article.
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), Gilead Sciences, Inc. (GILD) and Medtronic plc (MDT), as well as two micro-cap stocks Cooper-Standard Holdings Inc. (CPS) and Rave Restaurant Group, Inc. (RAVE).
4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty
by Urmimala Biswas
Here are four PEG-based GARP picks, GILD, EXEL, SYF and TAP, which qualify our screening criteria.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH